Studies have shown that CARs with moderateaffinities are better suited to distinguish low versus high densityof antigens on target cells and, hence, are designed in some clinicaltreatments to specifically avoid off-tumor toxicity against healthytissues/cells expressing low levels of target antigen.35−39 Thus, the monobody CAR in this report was engineered with moderatebinding affinity and potentially could specifically target cancercells with high PD-L1 density which tend to resist drug treatment40 while sparing bystander cells expressing lowlevels of PD-L1. The gene discussed is CD274; the disease is neoplasm.